Elanco Animal Health Incorporated Q4 2025 Earnings Call Summary

Achieved 9% organic constant currency revenue growth in Q4, marking 10 consecutive quarters of underlying growth led by U.S. farm and pet health sectors. Innovation revenue reached $892 million in 2025, outperforming expectations due to the rapid adoption of the 'Big Six' products, particularly Credelio Quattro and Zenrelia. Credelio Quattro has become the fastest blockbuster in company history, gaining significant share in the $1.4 billion U.S. broad-spectrum parasiticide market through its unique fo ...